Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Fiscal Q3 revenue grew 23%, management raised its full-year outlook and forecast adjusted EBITDA breakeven next quarter. Shares gained about 22% through September 25 and closed near their recent high.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Persistent Losses ⢠Liquidity Decline ⢠Negative Cashflow TWST's improved gross margin is offset by persistent losses, weakening liquidity and cash flow, and an elevated valuation, suggesting caution despite adequate balance-sheet flexibility.
Price Behavior
Key Price Behavior Insights: ⢠Strong breakout ⢠Overbought momentum ⢠Key support Support Level: $155â156; $143â145 Resistance Level: New period high TWST surged 22.5% over the last month to a new high, but RSI near 70 signals pullback risk; bullish momentum holds above $155â156, while a break below $143â145 would weaken the trend.
Sentiment & News
Key News Insights: ⢠Eli Lilly deal ⢠Raised revenue guidance ⢠Profitability gap Twist Biosciences gains AI drug-discovery momentum and institutional backing, but its high valuation still hinges on achieving profitability.
AI Summary
TWST's upside now hinges on converting the Lilly TuneLab validation and 49% therapeutics growth into recurring, high-margin AI data-services revenue and reaching FY2026 Q4 adjusted EBITDA breakeven; with the stock already priced for this outcome, investors should require proof of cash-flow improvement and limited further dilution before adding exposure.
Description
Twist Bioscience is a synthetic biology company that manufactures synthetic DNA using a silicon-based platform that writes DNA on a chip. Its product portfolio serves research and development needsâfrom synthetic genes and sample-preparation reagents to antibody libraries for therapeutic discovery and experimental DNA data storageâand the company maintains collaborations with diagnostics and pharmaceutical partners, including Kyowa Kirin, Boehringer Ingelheim, and several specialist firms. Founded in 2013, Twist is headquartered in South San Francisco, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 25 | Oct 2 | TWST | Twist Bioscience Corporation | Fiscal Q3 revenue grew 23%, management raised its full-year outlook and forecast adjusted EBITDA breakeven next quarter. Shares gained about 22% through September 25 and closed near their recent high. | Active | +0.0% |